ONTOLOGY REPORT - ANNOTATIONS
| Term: | ibuprofen |
|
| Accession: | CHEBI:5855
|
browse the term
|
| Definition: | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group. |
| Synonyms: | exact_synonym: | 2-[4-(2-methylpropyl)phenyl]propanoic acid |
| | related_synonym: | (+-)-2-(p-isobutylphenyl)propionic acid; (+-)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; (+-)-p-isobutylhydratropic acid; (4-isobutylphenyl)-alpha-methylacetic acid; (RS)-ibuprofen; 2-(4-isobutylphenyl)propanoic acid; 4-isobutylhydratropic acid; Adran; Advil; Amibufen; Anco; Anflagen; Apsifen; Bluton; Brufen; Brufort; Buburone; Butylenin; C13H18O2; CC(C)Cc1ccc(cc1)C(C)C(O)=O; Dolgin; Dolgirid; Dolgit; Dolo-Dolgit; Ebufac; Epobron; Femadon; Haltran; Ibu-Attritin; Ibumetin; Ibuprocin; Ibutid; InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15); InChIKey=HEFNNWSXXWATRW-UHFFFAOYSA-N; Inabrin; Inoven; Lamidon; Lebrufen; Liptan; Medipren; Motrin; Mynosedin; Nobfen; Nobgen; Nuprin; Nurofen; Pediaprofen; Roidenin; Rufen; Seclodin; Suspren; Tabalon; Trendar; Urem; alpha-(4-isobutylphenyl)propionic acid; alpha-(p-isobutylphenyl)propionic acid |
| | xref_casrn: | 15687-27-1 |
| | xref: | ChEMBL:111674 "ChEMBL COMPOUND"; ChemIDplus:15687-27-1 "CAS Registry Number"; ChemIDplus:2049713 "Beilstein Registry Number"; CiteXplore:11433218 "PubMed citation"; CiteXplore:12723739 "PubMed citation"; CiteXplore:14562167 "PubMed citation"; CiteXplore:15506544 "PubMed citation"; CiteXplore:18335846 "PubMed citation"; CiteXplore:18697608 "PubMed citation"; CiteXplore:21368281 "PubMed citation"; DrugBank:DB01050 "DrugBank"; KEGG COMPOUND:15687-27-1 "CAS Registry Number"; KEGG COMPOUND:C01588 "KEGG COMPOUND"; KEGG DRUG:D00126 "KEGG DRUG" |
| | xref_mesh: | MESH:D007052 |
| | xref: | NIST Chemistry WebBook:15687-27-1 "CAS Registry Number"; Patent:GB971700 "Patent"; Patent:US3228831 "Patent"; Patent:US3385886 "Patent"; Patent:US5215755 "Patent"; Patent:US6727286 "Patent"; Reaxys:2049713 "Reaxys Registry Number"; Wikipedia:Ibuprofen "Wikipedia" |
|
|
ibuprofen
|
| G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
|
increases metabolic processing |
EXP |
16 |
49,036,892 |
49,081,416 |
RGD:6480464 |
CTD |
| G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
|
increases metabolic processing |
EXP |
10 |
39,729,805 |
39,778,106 |
RGD:6480464 |
CTD |
| G |
Adamts8 |
ADAM metallopeptidase with thrombospondin type 1 motif, 8 |
|
increases expression |
ISO |
8 |
30,732,584 |
30,743,809 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
|
decreases activity |
ISO |
17 |
77,084,306 |
77,112,994 |
RGD:6480464 |
CTD |
| G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
decreases activity |
ISO |
17 |
77,034,737 |
77,081,406 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
decreases activity |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
|
affects expression |
ISO |
10 |
55,917,373 |
55,926,321 |
RGD:6480464 |
CTD |
| G |
Aloxe3 |
arachidonate lipoxygenase 3 |
|
affects expression |
ISO |
10 |
55,885,573 |
55,908,641 |
RGD:6480464 |
CTD |
| G |
Amacr |
alpha-methylacyl-CoA racemase |
|
affects response to substance |
ISO |
2 |
60,332,292 |
60,344,326 |
RGD:6480464 |
CTD |
| G |
Amacr |
alpha-methylacyl-CoA racemase |
|
multiple interactions |
ISO |
2 |
60,332,292 |
60,344,326 |
RGD:6480464 |
CTD |
| G |
Amacr |
alpha-methylacyl-CoA racemase |
|
increases metabolic processing |
ISO |
2 |
60,332,292 |
60,344,326 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
affects expression |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa2 |
annexin A2 |
|
affects expression |
ISO |
8 |
73,897,618 |
73,934,041 |
RGD:6480464 |
CTD |
| G |
Anxa3 |
annexin A3 |
|
affects expression |
ISO |
14 |
14,245,112 |
14,297,100 |
RGD:6480464 |
CTD |
| G |
Anxa9 |
annexin A9 |
|
decreases expression |
ISO |
2 |
190,206,342 |
190,215,046 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
affects cleavage |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
decreases expression |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
affects cleavage |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Asic1 |
acid-sensing (proton-gated) ion channel 1 |
|
decreases expression |
EXP |
7 |
138,414,656 |
138,443,272 |
RGD:6480464 |
CTD |
| G |
Asic1 |
acid-sensing (proton-gated) ion channel 1 |
|
decreases activity |
EXP |
7 |
138,414,656 |
138,443,272 |
RGD:6480464 |
CTD |
| G |
Asic2 |
acid-sensing (proton-gated) ion channel 2 |
|
decreases expression |
EXP |
10 |
69,103,244 |
70,190,305 |
RGD:6480464 |
CTD |
| G |
Asic3 |
acid-sensing (proton-gated) ion channel 3 |
|
decreases expression |
EXP |
4 |
6,125,614 |
6,129,660 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
multiple interactions |
ISO |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
decreases activity |
ISO |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
decreases expression |
ISO |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
multiple interactions |
ISO |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
decreases expression |
ISO |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
decreases expression |
EXP |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cacna2d3 |
calcium channel, voltage-dependent, alpha2/delta subunit 3 |
|
affects expression |
ISO |
16 |
4,173,412 |
5,059,574 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
decreases expression |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
multiple interactions |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
increases expression |
ISO |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cdh3 |
cadherin 3 |
|
affects expression |
ISO |
19 |
36,343,823 |
36,393,819 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdsn |
corneodesmosin |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ceacam1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
affects expression |
ISO |
1 |
80,742,540 |
80,758,943 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
decreases activity |
ISO |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
multiple interactions |
ISO |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
multiple interactions |
ISO |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
affects expression |
ISO |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr2 |
cannabinoid receptor 2 (macrophage) |
|
multiple interactions |
ISO |
5 |
154,674,754 |
154,702,552 |
RGD:6480464 |
CTD |
| G |
Col11a1 |
collagen, type XI, alpha 1 |
|
affects expression |
ISO |
2 |
209,996,467 |
210,193,379 |
RGD:6480464 |
CTD |
| G |
Cx3cl1 |
chemokine (C-X3-C motif) ligand 1 |
|
affects expression |
ISO |
19 |
10,666,940 |
10,676,424 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
multiple interactions |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
EXP |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
decreases metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects binding |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
decreases metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
affects metabolic processing |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
decreases metabolic processing |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
increases metabolic processing |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Ddx1 |
DEAD (Asp-Glu-Ala-Asp) box helicase 1 |
|
affects expression |
ISO |
6 |
36,794,602 |
36,825,473 |
RGD:6480464 |
CTD |
| G |
Dsc1 |
desmocollin 1 |
|
affects expression |
ISO |
18 |
11,953,172 |
11,979,048 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
multiple interactions |
ISO |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
increases phosphorylation |
ISO |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Elavl1 |
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) |
|
multiple interactions |
ISO |
12 |
1,459,046 |
1,500,042 |
RGD:6480464 |
CTD |
| G |
Elavl1 |
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) |
|
increases expression |
ISO |
12 |
1,459,046 |
1,500,042 |
RGD:6480464 |
CTD |
| G |
Eno1 |
enolase 1, (alpha) |
|
affects expression |
ISO |
5 |
167,394,131 |
167,405,516 |
RGD:6480464 |
CTD |
| G |
Epas1 |
endothelial PAS domain protein 1 |
|
decreases expression |
ISO |
6 |
10,203,108 |
10,297,215 |
RGD:6480464 |
CTD |
| G |
Ephb6 |
Eph receptor B6 |
|
affects expression |
ISO |
4 |
69,316,600 |
69,331,856 |
RGD:6480464 |
CTD |
| G |
Erbb4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
affects cleavage |
ISO |
9 |
66,843,898 |
67,967,970 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
increases expression |
ISO |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Faah |
fatty acid amide hydrolase |
|
decreases activity |
EXP |
5 |
136,310,965 |
136,329,817 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
decreases expression |
ISO |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fosb |
FBJ osteosarcoma oncogene B |
|
increases expression |
ISO |
1 |
78,668,497 |
78,673,330 |
RGD:6480464 |
CTD |
| G |
Frzb |
frizzled-related protein |
|
affects expression |
ISO |
3 |
63,350,504 |
63,383,436 |
RGD:6480464 |
CTD |
| G |
Gata3 |
GATA binding protein 3 |
|
decreases expression |
ISO |
17 |
79,991,587 |
80,011,574 |
RGD:6480464 |
CTD |
| G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
|
increases expression |
ISO |
8 |
82,724,429 |
82,762,848 |
RGD:6480464 |
CTD |
| G |
Gclm |
glutamate cysteine ligase, modifier subunit |
|
increases expression |
ISO |
2 |
218,895,434 |
218,915,491 |
RGD:6480464 |
CTD |
| G |
Gdf15 |
growth differentiation factor 15 |
|
increases expression |
ISO |
16 |
19,310,882 |
19,313,465 |
RGD:6480464 |
CTD |
| G |
Gdf15 |
growth differentiation factor 15 |
|
increases expression |
ISO |
16 |
19,310,882 |
19,313,465 |
RGD:6480464 |
CTD |
| G |
Gdf15 |
growth differentiation factor 15 |
|
multiple interactions |
ISO |
16 |
19,310,882 |
19,313,465 |
RGD:6480464 |
CTD |
| G |
Gstt1 |
glutathione S-transferase theta 1 |
|
increases expression |
EXP |
20 |
13,604,355 |
13,621,456 |
RGD:6480464 |
CTD |
| G |
Gstt2 |
glutathione S-transferase, theta 2 |
|
increases expression |
EXP |
20 |
13,221,696 |
13,225,367 |
RGD:6480464 |
CTD |
| G |
Hif1a |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
decreases expression |
ISO |
6 |
96,419,024 |
96,463,891 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
affects expression |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
increases expression |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
increases activity |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hsf1 |
heat shock transcription factor 1 |
|
increases activity |
ISO |
7 |
114,524,211 |
114,551,166 |
RGD:6480464 |
CTD |
| G |
Hspa1a |
heat shock protein 1A |
|
affects localization |
ISO |
20 |
3,945,716 |
3,959,552 |
RGD:6480464 |
CTD |
| G |
Hspa1a |
heat shock protein 1A |
|
increases expression |
ISO |
20 |
3,945,716 |
3,959,552 |
RGD:6480464 |
CTD |
| G |
Hspa8 |
heat shock 70kDa protein 8 |
|
affects localization |
ISO |
8 |
43,784,035 |
43,787,760 |
RGD:6480464 |
CTD |
| G |
Hspa8 |
heat shock 70kDa protein 8 |
|
affects localization |
ISO |
8 |
43,784,035 |
43,787,760 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
decreases expression |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases secretion |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases expression |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
increases expression |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
affects expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
decreases secretion |
ISO |
3 |
2,607,800 |
2,613,216 |
RGD:6480464 |
CTD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
multiple interactions |
EXP |
3 |
2,607,800 |
2,613,216 |
RGD:6480464 |
CTD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
increases expression |
EXP |
3 |
2,607,800 |
2,613,216 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Insm1 |
insulinoma-associated 1 |
|
decreases expression |
ISO |
3 |
134,845,568 |
134,847,243 |
RGD:6480464 |
CTD |
| G |
Itgbl1 |
integrin, beta-like 1 |
|
affects expression |
ISO |
15 |
108,785,509 |
109,051,028 |
RGD:6480464 |
CTD |
| G |
Ldhb |
lactate dehydrogenase B |
|
affects expression |
ISO |
4 |
180,061,567 |
180,079,473 |
RGD:6480464 |
CTD |
| G |
Ldlr |
low density lipoprotein receptor |
|
multiple interactions |
ISO |
8 |
20,824,040 |
20,846,920 |
RGD:6480464 |
CTD |
| G |
Lgals1 |
lectin, galactoside-binding, soluble, 1 |
|
affects expression |
ISO |
7 |
116,893,662 |
116,896,768 |
RGD:6480464 |
CTD |
| G |
Lta |
lymphotoxin alpha (TNF superfamily, member 1) |
|
affects response to substance |
ISO |
20 |
3,657,842 |
3,659,848 |
RGD:6480464 |
CTD |
| G |
Ltbr |
lymphotoxin beta receptor (TNFR superfamily, member 3) |
|
decreases expression |
ISO |
4 |
161,431,864 |
161,438,265 |
RGD:6480464 |
CTD |
| G |
Ly9 |
lymphocyte antigen 9 |
|
decreases expression |
ISO |
13 |
87,581,203 |
87,600,810 |
RGD:6480464 |
CTD |
| G |
Mal |
mal, T-cell differentiation protein |
|
increases expression |
ISO |
3 |
115,166,671 |
115,190,432 |
RGD:6480464 |
CTD |
| G |
Mapk11 |
mitogen-activated protein kinase 11 |
|
multiple interactions |
ISO |
7 |
127,444,055 |
127,449,990 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapkapk2 |
mitogen-activated protein kinase-activated protein kinase 2 |
|
multiple interactions |
ISO |
13 |
43,994,943 |
44,041,504 |
RGD:6480464 |
CTD |
| G |
Mapkapk3 |
mitogen-activated protein kinase-activated protein kinase 3 |
|
multiple interactions |
ISO |
8 |
112,497,626 |
112,531,778 |
RGD:6480464 |
CTD |
| G |
Mapre2 |
microtubule-associated protein, RP/EB family, member 2 |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
increases expression |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
increases expression |
ISO |
8 |
4,315,601 |
4,329,146 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mta2 |
metastasis associated 1 family, member 2 |
|
increases expression |
ISO |
1 |
211,618,426 |
211,627,147 |
RGD:6480464 |
CTD |
| G |
Mxd1 |
max dimerization protein 1 |
|
increases expression |
ISO |
4 |
120,801,932 |
120,822,346 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
multiple interactions |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
multiple interactions |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
affects expression |
ISO |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases activity |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
affects expression |
ISO |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled, 2 |
|
multiple interactions |
ISO |
1 |
158,440,018 |
158,454,213 |
RGD:6480464 |
CTD |
| G |
Pabpn1 |
poly(A) binding protein, nuclear 1 |
|
multiple interactions |
ISO |
15 |
32,994,493 |
32,999,104 |
RGD:6480464 |
CTD |
| G |
Pdgfa |
platelet-derived growth factor alpha polypeptide |
|
multiple interactions |
ISO |
12 |
16,151,045 |
16,172,412 |
RGD:6480464 |
CTD |
| G |
Pgam1 |
phosphoglycerate mutase 1 (brain) |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Pgam1 |
phosphoglycerate mutase 1 (brain) |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
|
affects expression |
ISO |
5 |
157,654,786 |
157,657,360 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
multiple interactions |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Plec |
plectin |
|
increases expression |
ISO |
7 |
114,202,742 |
114,262,385 |
RGD:6480464 |
CTD |
| G |
Plec |
plectin |
|
affects expression |
ISO |
7 |
114,202,742 |
114,262,385 |
RGD:6480464 |
CTD |
| G |
Pml |
promyelocytic leukemia |
|
affects expression |
ISO |
8 |
62,020,438 |
62,051,927 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
increases activity |
EXP |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases activity |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ppia |
peptidylprolyl isomerase A (cyclophilin A) |
|
affects expression |
ISO |
14 |
87,165,998 |
87,169,995 |
RGD:6480464 |
CTD |
| G |
Ppp1ca |
protein phosphatase 1, catalytic subunit, alpha isozyme |
|
multiple interactions |
ISO |
1 |
206,774,719 |
206,778,336 |
RGD:6480464 |
CTD |
| G |
Prdx2 |
peroxiredoxin 2 |
|
affects expression |
ISO |
19 |
24,836,199 |
24,841,390 |
RGD:6480464 |
CTD |
| G |
Prdx2 |
peroxiredoxin 2 |
|
increases expression |
ISO |
19 |
24,836,199 |
24,841,390 |
RGD:6480464 |
CTD |
| G |
Prdx6 |
peroxiredoxin 6 |
|
affects expression |
ISO |
13 |
76,824,968 |
76,835,517 |
RGD:6480464 |
CTD |
| G |
Ptger3 |
prostaglandin E receptor 3 (subtype EP3) |
|
affects expression |
ISO |
2 |
255,680,691 |
255,759,202 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases expression |
EXP |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases response to substance |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases degradation |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Pxn |
paxillin |
|
decreases expression |
EXP |
12 |
42,322,193 |
42,370,507 |
RGD:6480464 |
CTD |
| G |
Pyy |
peptide YY (mapped) |
|
decreases expression |
ISO |
10 |
91,174,365 |
91,175,488 |
RGD:6480464 |
CTD |
| G |
Ran |
RAN, member RAS oncogene family |
|
affects expression |
ISO |
12 |
28,736,786 |
28,739,921 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
decreases phosphorylation |
EXP |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
|
increases expression |
ISO |
X |
61,634,964 |
61,638,247 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
|
decreases activity |
ISO |
1 |
42,351,239 |
42,378,295 |
RGD:6480464 |
CTD |
| G |
Slc22a24 |
solute carrier family 22, member 24 |
|
multiple interactions |
EXP |
1 |
210,409,224 |
210,465,549 |
RGD:6480464 |
CTD |
| G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
|
decreases activity |
ISO |
1 |
211,294,178 |
211,302,398 |
RGD:6480464 |
CTD |
| G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
|
increases uptake |
ISO |
1 |
211,294,178 |
211,302,398 |
RGD:6480464 |
CTD |
| G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
|
multiple interactions |
ISO |
9 |
9,934,309 |
9,940,107 |
RGD:6480464 |
CTD |
| G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
|
decreases activity |
ISO |
9 |
9,934,309 |
9,940,107 |
RGD:6480464 |
CTD |
| G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
|
multiple interactions |
ISO |
1 |
211,269,366 |
211,287,596 |
RGD:6480464 |
CTD |
| G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
|
multiple interactions |
ISO |
1 |
211,269,366 |
211,287,596 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
decreases expression |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc5a8 |
solute carrier family 5 (iodide transporter), member 8 |
|
decreases activity |
ISO |
7 |
25,585,545 |
25,626,486 |
RGD:6480464 |
CTD |
| G |
Slc5a8 |
solute carrier family 5 (iodide transporter), member 8 |
|
decreases activity |
ISO |
7 |
25,585,545 |
25,626,486 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
multiple interactions |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Socs3 |
suppressor of cytokine signaling 3 |
|
affects expression |
ISO |
10 |
107,958,468 |
107,959,330 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
increases expression |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sult1e1 |
sulfotransferase family 1E, estrogen-preferring, member 1 |
|
decreases activity |
ISO |
14 |
21,948,475 |
21,965,541 |
RGD:6480464 |
CTD |
| G |
Tbx21 |
T-box 21 |
|
decreases expression |
ISO |
10 |
85,817,743 |
85,834,178 |
RGD:6480464 |
CTD |
| G |
Thbs1 |
thrombospondin 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tmprss4 |
transmembrane protease, serine 4 |
|
affects expression |
ISO |
8 |
48,120,501 |
48,154,809 |
RGD:6480464 |
CTD |
| G |
Tnc |
tenascin C |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases secretion |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf21 |
tumor necrosis factor receptor superfamily, member 21 |
|
multiple interactions |
ISO |
9 |
13,587,961 |
13,666,380 |
RGD:6480464 |
CTD |
| G |
Tnfrsf21 |
tumor necrosis factor receptor superfamily, member 21 |
|
decreases expression |
ISO |
9 |
13,587,961 |
13,666,380 |
RGD:6480464 |
CTD |
| G |
Tpi1 |
triosephosphate isomerase 1 |
|
increases expression |
ISO |
4 |
160,933,341 |
160,936,871 |
RGD:6480464 |
CTD |
| G |
Tpi1 |
triosephosphate isomerase 1 |
|
affects expression |
ISO |
4 |
160,933,341 |
160,936,871 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
increases glucuronidation |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a8 |
UDP glycosyltransferase 1 family, polypeptide A8 |
|
increases glucuronidation |
ISO |
9 |
87,017,029 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a9 |
UDP glucuronosyltransferase 1 family, polypeptide A9 |
|
increases glucuronidation |
ISO |
9 |
86,986,915 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt2b15 |
UDP glucuronosyltransferase 2 family, polypeptide B15 |
|
increases glucuronidation |
ISO |
14 |
22,346,334 |
22,366,860 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
increases glucuronidation |
ISO |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
increases glucuronidation |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
multiple interactions |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
increases glucuronidation |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
increases glucuronidation |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
increases glucuronidation |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
| G |
UST4r |
integral membrane transport protein UST4r |
|
decreases activity |
ISO |
1 |
210,618,706 |
210,688,125 |
RGD:6480464 |
CTD |
| G |
UST4r |
integral membrane transport protein UST4r |
|
increases uptake |
ISO |
1 |
210,618,706 |
210,688,125 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases secretion |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
Term paths to the root
|